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Bisphosphonates (BP) prevent, reduce, and delay cancer-related skeletal complications in patients, and have
substantially decreased the prevalence of such events since their introduction. Today, a broad range of BP with
differences in potency, efficacy, dosing, and administration as well as approved indications is available. In
addition, results of clinical trials investigating the efficacy of BP in cancer treatment-induced bone loss (CTIBL)
have been recently published. The purpose of this paper is to review the current evidence on the use of BP in
solid tumours and provide clinical recommendations. An interdisciplinary expert panel of clinical oncologists
and of specialists in metabolic bone diseases assessed the widespread evidence and information on the
efficacy of BP in the metastatic and nonmetastatic setting, as well as ongoing research on the adjuvant use of
BP. Based on available evidence, the panel recommends amino-bisphosphonates for patients with metastatic
bone disease from breast cancer and zoledronic acid for patients with other solid tumours as primary disease.
Dosing of BP should follow approved indications with adjustments if necessary. While i.v. administration is most
often preferable, oral administration (clodronate, IBA) may be considered for breast cancer patients who cannot
or do not need to attend regular hospital care. Early-stage cancer patients at risk of developing CTIBL should be
considered for preventative BP treatment. The strongest evidence in this setting is now available for ZOL. Overall,
BP are well-tolerated, and most common adverse events are influenza-like syndrome, arthralgia, and when used
orally, gastrointestinal symptoms. The dose of BP may need to be adapted to renal function and initial creatinine
clearance calculation is mandatory according to the panel for use of any BP. Subsequent monitoring is
recommended for ZOL and PAM, as described by the regulatory authority guidelines. Patients scheduled to
receive BP (mainly every 3–4 weeks i.v.) should have a dental examination and be advised on appropriate
measures for reducing the risk of jaw osteonecrosis. BP are well established as supportive therapy to reduce the
frequency and severity of skeletal complications in patients with bone metastases from different cancers.
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introduction
Bisphosphonates (BP) reduce and delay skeletal morbidity and
the resulting complications of osteoporosis and skeletal
morbidity due to metastatic bone disease (MBD). BP have
therefore been used for >15 years to improve the outcome
of patients with bone metastases from solid tumours. In
recent years, a wealth of publications on BP efficacy and
safety was generated, providing a rationale for guidelines on
the use of various BP compounds in solid tumours,
particularly with respect to administration route, dose
optimization, initiation, duration, and monitoring of therapy.
This paper offers clinical recommendations on the role of
BP in the metastatic and nonmetastatic settings, reflecting
re
v
ie
w
*Correspondence to: Dr M. Aapro, IMO Clinique de Genolier, Route du Muids 1,
1272 Genolier, Switzerland. Tel: +41-22-366-91-34; Fax: +41-22-366-91-31;
E-mail: maapro@genolier.net
ª The Author 2007. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org
consensus of an interdisciplinary expert group based on
a concise review of available evidence. The recommendations
were drafted at a consensus meeting followed by reviews of
manuscript drafts circulated within the panel. These
recommendations should be understood as an auxiliary tool for
supporting and informing individual clinicians’ decisions
regarding choice and implementation of BP therapy in patients
with solid tumours.
BP effectively inhibit osteoclast-mediated bone resorption
[1], thus providing the rationale for their use for skeletal
protection in osteoporosis [2] as well as in various stages in the
natural history of solid tumours [1]. BP compounds are
remarkably variable in structure and resulting physicochemical
and biological properties [1], including potency[3]. The newer,
nitrogen-containing bisphosphonates (N-BP) such as
ibandronate (IBA), pamidronate (PAM), risedronate (RIS), and
zoledronic acid (ZOL) are several orders of magnitude more
potent than earlier generation BP such as etidronate,
tiludronate and clodronate (CLO). While non-N-BP are
incorporated into adenosine triphosphate (ATP)-containing
compounds, thus inhibiting cell function [4], N-BP interfere
with cell signalling and block the prenylation of small signalling
proteins (e.g. Ras, Rho) which are essential for cell function
and survival [5, 6]. Farnesyl pyrophosphate synthase was
proposed as main enzymic target of N-BP [5]; however, more
recent reports indicate that the main biological activity of
N-BP is directed against protein geranylgeranylation [6]. Non-
N-BP induce production of a unique ATP analogue that can
directly induce apoptosis [3]. The variability in structure
and potency (Figure 1 as electronic supplement) has substantial
biological and clinical implications [1].
MBD is commonly seen with various cancer types, including
frequent ones such as those of the breast and prostate.
Accordingly, bone metastases affect a multitude of patients with
advanced disease (e.g. >60% of patients with metastatic
breast cancer [7]). They often lead to skeletal complications,
such as pain, pathological fractures requiring surgery and/or
radiation to bone, spinal cord compression, or hypercalcaemia
of malignancy [8–10], many of which are associated with life-
altering morbidity and can negatively impact survival times.
Pathologic fractures are the most common skeletal events,
reflecting the fragility of patients’ bones and the burden of bone
pain. Many patients will have to receive radiation to bone as
treatment for bone pain and in order to prevent complications.
Moreover, skeletal events are associated with a loss of
mobility and social functioning, a decrease in quality of life
(QoL) [11–13], and with a substantial increase in medical
costs [14].
To date, BP are the key treatment option for reducing,
delaying and preventing skeletal complications associated with
bone metastases, thus maintaining and restoring patient’s
mobility and function and reducing pain [15]. Health
economic studies on BP indicate that they are a cost-effective
treatment considering drug costs, QoL benefits (especially due
to bone pain reduction), and incidence and costs of skeletal
complications [16–18]. The choice of BP for a given clinical
setting should be evidence based.
In nonmetastatic, early-stage cancer, BP were shown in
clinical trials to be effective in preventing cancer treatment-
induced bone loss (CTIBL) due to hormone deprivation
therapy [19–21]. Moreover, some evidence that they may
prevent bone metastasis [22, 23] has resulted in a large trial
program investigating this hypothesis.
It is finally recommended to consider the use of calcium
(1 g/day) and vitamin D3 (800 IU/day) whenever BP are used.
use of BP in metastatic cancer
The skeleton is the preferred site of metastasis for many solid
tumours. Across different solid tumour types the prevalence of
MBD is highest in breast and prostate cancer (65%–75%)
followed by thyroid (60%), lung (40%), and bladder cancer
(30%–40%) [24]. As malignant bone lesions are characterized
by a disordered bone metabolism, all patients with MBD are at
risk of developing skeletal complications (Table 1). Skeletal
complications are also associated with increased mortality [25].
Therefore, patients with MBD, irrespective of the cancer type,
are in need of and should be considered for a therapy that
effectively inhibits bone resorption. BP, mostly compared with
placebo, have been proven to reduce and delay the occurrence
of skeletal events [7] and control bone pain in patients with
MBD [15, 26–28], thereby preserving mobility, social
functioning, and QoL over the course of progressive metastatic
disease [12, 13, 28]. BP efficacy has been quantified using
various definitions of skeletal complications, measures, and
methods for statistical analysis (Table 1). Moreover, sample size
may influence the statistical significance of the outcome. This
should be borne in mind when interpreting trial data.
breast cancer
Nearly 70% of breast cancer patients treated with placebo in
controlled BP trials experience more than one skeletal-related
event (SRE), and 50% have a pathological fracture >2-year
period [29]. Experience of a pathological fracture increases the
risk of death in breast cancer patients by 32% [25]. Several
clinical trials using different measures of SRE as a composite
Figure 1. In vivo potency of bisphosphonates correlates with in vitro
potency. Differences in structure of the bisphosphonates have strong
influence on the potency.
Annals of Oncology review
Volume 19 |No. 3 |March 2008 doi:10.1093/annonc/mdm442 | 421
end point have shown the benefits of BP to patients with
advanced breast cancer (Table 2) [38]. Currently, four BP
are approved for the treatment of MBD in breast cancer: oral
CLO, oral or i.v. IBA, i.v. PAM, and i.v. ZOL. Meta-analysis of
eight trials including women with advanced breast cancer
and existing bone metastasis showed a 17% reduction in the
risk of developing a skeletal event for patients on BP therapy
[37]. Together with PAM, ZOL is the only i.v. BP
demonstrating a statistically significant clinical benefit across
multiple end points [26, 30, 36, 39]. The only head-to-head
comparison of two BP in an appropriately powered phase III
study was between ZOL and PAM [36]. In this study, the
proportion of patients with at least one SRE was similar for
ZOL and PAM; however, ZOL reduces the overall risk of
developing any skeletal complications by 20% when compared
with PAM [relative risk (RR) = 0.799; P = 0.025] [36, 40, 41].
In the subset of patients with lytic bone lesions, the greater
efficacy of ZOL over PAM was demonstrated [41]. The efficacy
of BP against bone pain was investigated by several trials and is
shown for pooled studies of oral IBA (P = 0.001), i.v. IBA
(P = 0.0006), oral CLO (P = 0.01), and PAM (P < 0.001) [15].
In a prospective placebo-controlled study, ZOL consistently
reduced brief pain inventory composite pain scores at each
evaluation carried out throughout a 12-month period
(P < 0.05) [26]. Moreover, it has shown that oral IBA and i.v.
ZOL can reduce bone turnover markers [42]; however current
evidence does not support the use of bone markers as basis for
clinical decision making.
On the grounds of efficacy data (which are difficult to
interpret due to the lack of a multiple event analysis and
suboptimal compliance) [33, 43], the panel recommends to
offer an N-BP to breast cancer patients with MBD.
prostate cancer
Prostate cancer commonly metastasizes to bone; this can lead
to significant skeletal morbidity. Although BP are known to
reduce excessive bone turnover while preserving bone structure
and mineralization in patients with breast cancer, in prostate
cancer efficacy data differ (Table 3). ZOL significantly
reduced the incidence of SREs by 36% [hazard ratio
(HR) = 0.640; P = 0.002] and delayed the first SRE by >5
months (P = 0.009) [52] compared with placebo. ZOL also
provided significant long-term reductions in bone pain
compared with placebo [53].
In contrast, several randomized, placebo-controlled trials of
early generation BP (etidronate (ETI), CLO, PAM) showed no
statistically significant clinical benefit in patients with bone
metastases from prostate cancer. Although results indicative of
benefit were reported (Table 3), neither oral nor i.v. CLO
showed statistically significant pain relief [45, 46, 55] or any
significant improvement of symptomatic bone progression-free
survival (P = 0.066) [46]. Also, PAM failed to demonstrate a
significant overall treatment benefit compared with placebo in
palliation of bone pain, improvement of QoL, or reduction
of SREs [51] in patients with bone pain and disease progression
after first-line hormonal therapy. In a small open-label,
nonrandomized study (n = 25), i.v. IBA was shown to be
effective for reducing pain from prostate cancer metastasized
to bone [49]; efficacy in terms of reduction of skeletal events
was not measured.
Based on the available evidence demonstrating a significantly
lower incidence of skeletal complications as well as durable pain
palliation, the opinion of the panel is that ZOL is presently
the BP treatment of choice for patients with hormone
refractory prostate cancer metastatic to bone. And it has been
published that SRE reduction is greatest in patients
without pain, thus patients should probably not have to
wait for symptoms before starting ZOL therapy in this setting
[56, 57].
lung cancer
ZOL reduced the risk of developing an SRE by 31%
(HR = 0.693, P = 0.003) in a double-blind, placebo-controlled,
21-month trial that included 773 patients with lung cancer
and other solid tumours (except breast and prostate; 244 with
non-small-cell lung cancer (NSCLC) and 36 with small-cell
lung cancer) [58, 59]. Therefore, the panel recommends that
lung cancer patients with bone metastases and a reasonable
chance of benefiting (i.e. expected survival times, patients
performance status, etc.) should be considered for ZOL
treatment. Further prospective clinical trials are warranted
to better define the role of BP in the treatment strategy of
NSCLC, with particular emphasis on locally advanced stage IIIB
disease after completion of chemo/radiotherapy.
Table 1. Measuring therapeutic benefit of bisphosphonates in patients
with bone metastasis
Goal of therapy Relevant end point
Prevent skeletal complications/bone
eventsa
Percent of patients with ‡1 event
Delay onset of skeletal complications Time to first event
Reduce the rate of occurrence of
complications
SMR or SMPRb
Reduce the number of complications
and/or delay the time to the first and
subsequent complications, thereby
reducing overall skeletal morbidity
Multiple event analysesc
aDefinition of skeletal complications/bone events for different
bisphosphonates to assess the efficacy: clodronate: Fractures, radiotherapy,
hypercalcaemia of malignancies; pamidronate/zoledronic acid: fractures,
surgery to bone, radiation to bone, spinal cord compression, HCM; IBA:
fractures, radiation to bone, surgery to bone.
bSMR (events per year) or SMPR (number of 12-week periods on which
a patient experiences new bone event divided by the number of
periods on study) assess the number of events that occur during a defined
time period.
cIn contrast to the analysis of the proportion of patients with ‡1 skeletal
events or the time to first event, which ignore all events after the first one,
or skeletal morbidity (period) rates which fail to consider the timing of
events, multiple event analyses are statistically robust methods accounting
for all skeletal events and for the timing of events throughout the
course of disease. The result is expressed as a hazard ratio indicating the
reduction in the risk of skeletal events compared with control.
SMR, skeletal morbidity rate; SMPR, skeletal morbidity period rate.
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renal cell carcinoma and other solid
tumours
Renal cell cancer with lymph node metastases at primary
diagnosis often metastasizes to bone and patients are at high
risk of skeletal complications [60]. In 46 patients, ZOL reduced
the risk of having a SRE by 58% (HR = 0.418; P = 0.010) and
the incidence of SREs by 41% (HR = 0.590; P = 0.011).
Occurrence of the first SRE was delayed by 1 year (424 days
versus 72 days in the placebo group, P = 0.007) [58, 59].
ZOL is the only BP with data on reduction of SREs in
other tumour types, such as thyroid cancer (n = 6),
bladder cancer (n = 26), and 16 further types of solid tumours
(n = 143) [58, 59]. In the subset ‘other tumours’, ZOL
reduced the proportion of patients with SRE (33% versus 43%)
and extended the median time to first SRE to 314 days
compared with 168 in the placebo arm. Both outcomes did
not reach statistical significance (P = 0.11 and P = 0.051,
respectively) [59]. Some tolerability data have been reported for
i.v. IBA in colorectal carcinoma [61], and a further study in
different tumour types (n = 66) has shown decreased analgesic
requirement for patients with CLO treatment [62].
The panel recommends that ZOL should be considered in all
patients with bone metastases from renal cell carcinoma and
Table 2. Overview of the breast cancer trials with BP
BP Study N Dose Design and
control
1 end point Relative risk of
skeletal events RR
(95% confidence
interval)
i.v. IBA Body et al. [30] 462 2 or 6 mg  Double blind SMPR 0.82 (0.67, 1.00)
 Placebo
 Monthly, up to
2 years
p.o. IBA Body et al. [31] 564 50 mg  Double blind SMPR 0.86 (0.73, 1.02)
 Placebo
 Daily, up to 96
weeks
p.o. CLO Kristensen et al. [32] 100 1600 mg  Randomized Number of skeletal
events
0.69 (0.40, 1.20)
 Open label
 Controlled
 Daily, for 2 years
p.o. CLO Paterson et al. [33] 185 1600 mg  Double blind Combined rate of
morbid skeletal
events
0.83 (0.68, 1.02)
 Placebo
 Daily for 3 years
p.o. CLO Tubiana-Hulin et al. [34] 144 1600 mg  Randomized New bone event 0.92 (0.92, 1.19)
 Double blind
 Controlled
 Daily, up to 1 year
i.v. PAM Hortobagyi et al. [29]
Theriault et al. [35]
754 90 mg  Randomized Skeletal morbidity
rate (events/
per year)
0.77 (0.69, 0.87)a
 Double blind
 Placebo
 Every 3–4 weeks,
up to 24 cycles
i.v. ZOL Kohno et al. [26] 228 4 mg  Randomized SRE rate ratio 0.59 (0.42, 0.82)
 Double blind
 Placebo
 Every 4 weeks, for
1 year
i.v. ZOL Rosen et al. [36] 412b 4 mg  Randomized Proportion of patients
who experienced ‡1
SRE
0.80 (0.66, 0.97) [36]
 Double blind
 PAM
 Every 4 weeks, for
2 year
Trials investigating the effect of bisphosphonates at currently recommended doses on the overall risk of skeletal events in patients with advanced breast cancer
[37]. Primary end points were achieved in all trials; for better comparability, hazard ratios are indicated according to the Cochrane review paper [37]. The
value of such comparisons is, however, limited by marked heterogeneity in patient populations and study characteristics.
aCombined analysis of Aredia studies 18 and 19 [37].
bPatients (with bone lesions secondary to advanced breast carcinoma) that entered extension study.
BP, bisphosphonates; IBA, ibandronate; PAM, pamidronate; ZOL, zoledronic acid; CLO, clodronate; SRE, skeletal-related event; RR, relative risk.
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other solid tumours as discussed above, based on an assessment
of their expected survival time and an expectation of overall
palliative benefit.
choice of administration route
Oral administration (CLO, IBA) is approved in patients with
breast cancer, and should be considered for patients who cannot
or do not need to attend regular hospital care. Oral
administration requires precautionary measures to ensure
absorption and—for some BP—to avoid gastrointestinal (GI)
adverse event (AE) [63, 64]. The inconvenience and
complexity of oral dosing requirements, the potential for adverse
effects, especially when dosing recommendations are not
followed, and very low absorption rates of oral BP even under
ideal conditions, may contribute to poor outcomes [65].
Table 3. Overview of the prostate cancer trials with BP
BP Author N Dose Design 1 end point Results related to
pain or skeletal
events [44] RR
(95% confidence
interval)
CLO Elomaa et al. [45] 75 3.2 g/day (1st month)
1.6 g/day (p.o.)
 Randomized Pain relief Proportion of patients
with pain response
0.47 (0.15, 1.47)
CLO Dearnaley et al. [46]a 311 2080 mg/day (p.o.)  3-year trial Symptomatic BPFS Proportion of patients
with any skeletal
event 0.79
(0.50, 1.26)
 Randomized
 Double blind
placebo controlled
CLO Ernst et al. [47] 204 1500 mg/3 weeks (i.v.)  Randomized Palliative response Proportion of patients
with pain response
0.75 (0.42, 1.36)
ETI Smith [48] 57 200 mg b.i.d.  Randomized Pain relief Proportion of patients
with pain response
0.73 (0.14, 4.00)
 Double blind
 Placebo controlled
IBA Heidenreich [49, 50] 25 6 mg/4 weeks (i.v.)  Open Visual analog
pain score
Significant pain
reduction
(P < 0.001)
 Prospective
 Nonrandomized
PAM Small et al. [51] 378 90 mg/3 weeks (i.v.) 27-week trial BPI Proportion of patients
with any skeletal
event 0.98
(0.61, 1.58)
 Randomized Proportion with
pathological
fractures 1.26
(0.68, 2.32)
 Double blind Change in average BPI
score after 9 weeks
20.61 (PAM)
versus 0.44
(placebo); P = 0.46
 Placebo controlled
ZOL Saad [52–54] 643 4 mg/3 weeks  24-month trial
(15-months core
phase, 9-months
extension)
Percentage
of patients
with >1 SRE
Proportion of patients
with any skeletal
event 0.71
(0.50, 0.99)
 Randomized
 Double blind Proportion with
pathological
fractures 0.57
(0.38, 0.88)
 Placebo controlled
Trials investigating the effect of bisphosphonates at currently recommended doses on the outcome measures related to pain or skeletal events in patients with
hormone refractory prostate cancer (acommencing or responding to hormone therapy) [44]. A study on i.v. IBA indicating a significant pain reduction [49,
50] was not included in the Cochrane review since it was a nonrandomized study. Palliative response (present pain intensity minus 2 points or analgesic
intake reduced by 50%).
BP, bisphosphonates; RR, relative risk; CLO, clodronate; BPFS, bone progression-free survival; ETI, etidronate; IBA, ibandronate; PAM, pamidronate; BPI,
brief pain inventory; ZOL, zoledronic acid; SRE, skeletal-related event.
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Generally, i.v. administration (CLO, IBA, PAM, and ZOL)
is preferable since it can help ensuring adherence and
persistence compared with oral administration and can be
combined with infusions of nonnephrotoxic chemotherapy or
clinical monitoring of metastatic patients. Although i.v.
administration is usually done in an outpatient clinic setting,
delivery at the patient’s home has been evaluated [13] and can
be considered. Infusion time ranges from 15 min (ZOL, IBA)
up to 2 h (PAM).
adherence to and persistence with
BP therapy
Oral BP require regular intake, must be taken on an empty
stomach and—in case of IBA—in an upright position.
Therefore, all patients receiving oral BP need to be educated
about the pivotal importance of adherence to and persistence
with therapy. Both are known to be poor in patients self-
administering oral BP for osteoporosis [66, 67], even with
patient support [68], particularly with weekly or daily dosing
[2, 66]. In the metastatic setting, there are also reports of low
persistence [69, 70] that can be expected to jeopardize
therapeutic efficacy. In a study assessing patient preference for
either ZOL or PAM, 92% preferred ZOL because shorter
infusions caused less disruption to their daily schedule [71].
Compliance with CLO in the adjuvant and metastatic setting
has been reported to be acceptable [22].
initiation, dosing and duration of BP
therapy in metastatic cancer
There is a paucity of data for optimal use of BP, mainly
regarding initiation and treatment duration. To maximize the
benefit of BP treatment, the panel recommended—in the
absence of data—considering the start of therapy as soon as
bone metastases are diagnosed by radiographic techniques,
even if they are asymptomatic.
Dosing regimens of BP therapy for patients with bone
metastases should follow the evidence generated in clinical
studies. In patients with mild to moderate renal impairment
[creatinine clearance (CrCl) 30–60 ml/min], regulations
recommend lower doses of CLO and ZOL and longer infusion
times for PAM, respectively [63, 64, 72, 73]. A recent label of
IBA approved by European regulatory authorities allows
a dosing regimen of 6 mg >60 min instead of 15 min when CrCl
is 30–50 ml/min [74].
In patients with evidence of renal deterioration during
treatment, i.v. BP should be withheld and only resumed when
serum creatinine returns to within 10% of baseline [72].
However, in case of persistent renal deterioration, the panel
agreed that either dose reduction or longer infusion time
could be considered under close monitoring when clinical
assessment indicates that BP therapy should not be
discontinued. Because of the importance of continuing BP
treatment to prevent further SREs, discontinuation of
therapy should be limited to patients who cannot tolerate BP
therapy.
Treatment with ZOL is contraindicated in patients with
severe renal dysfunction (serum creatinine >265 lmol/l >3.0
mg/dl, CrCl <30 ml/min). In such cases, a reduced dose of 2 mg
i.v. IBA >60 min can be used in patients with breast cancer,
while there are no data for other tumours. Treatment with CLO
is contraindicated in patients with CrCl <10 ml/min or serum
creatinine >440 lmol/l.
Benefit of BP therapy with ZOL and IBA in breast cancer
has been shown for a treatment duration of up to 2 years
[36, 52, 59, 75]. Since the risk of SREs is going to continue, the
expert panel—in the absence of supporting data—recommends
continuation of therapy beyond 2 years but always based on
an individual risk assessment. Specifically, it should not be
discontinued once skeletal events occur, as controlled studies
with ZOL show a significant reduction in the risk of subsequent
skeletal events [52, 76]. In case of disease progression, the
anticancer treatment should be adapted according to the
patient’s clinical situation. In patients with disease progression
in the skeleton and pain despite the use of oral BP or PAM,
change to ZOL or IBA can improve pain control [77, 78].
use of bone markers in BP therapy
The use of bone markers for adjusting BP therapy and for the
prediction of patients’ risk of bone metastasis is under
investigation with ZOL (BISMARCK, OPTIMIZE). There is no
prospective trial at this point which shows that bone markers
are reliable for individual patients: they are only valid for
a cohort of patients in respective studies. Currently, the panel
does not recommend the use of bone markers in clinical
routine [42, 79, 80, 81].
elderly patients
There are no specific limitations for the use of BP in the elderly.
An International Society of Geriatric Oncology task force
reviewed information from the literature on BP in elderly
patients with bone metastases. They recommended that CrCl
(because serum creatinine values can be misleading in the
elderly) should be monitored in every patient, and an agent
with best possible renal tolerability should be used where
evidence of similar efficacy is available. The assessment and
optimization of hydration status was recommended in this
often dehydrated population [82].
managing QoL with BP
One goal of BP therapy in metastatic cancer is to keep patients
functional and mobile for as long as possible, thus preserving
their QoL and delaying its deterioration. Reduction and
postponement of skeletal complications and the associated life-
altering morbidity is essential for this purpose [11, 12, 83–86].
New tools for measuring QoL in routine practice are being
developed and need to be validated in different countries.
pain control and BP
Adequate pain control is a key aspect of QoL maintenance in
patients with bone metastases. Analgesic therapy should follow
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a stepwise escalation regimen as per World Health
Organization guidelines [87]. Along with analgesics, BP therapy
is a major factor contributing to the preservation of QoL in
patients with progressive metastatic disease [11, 12, 28, 31, 50,
83, 88–92]. Controlled clinical studies have shown BP
therapy, apart from its benefits in terms of skeletal morbidity,
to reduce bone pain including opioid-resistant pain, and
over the course of progressive disease to maintain it at lower
levels compared with controls [15].
concomitant BP therapy given with
anticancer therapy
A growing body of preclinical evidence from in vitro studies
and animal models demonstrates that BP can reduce skeletal
tumour burden and prevent metastasis to bone [93]. N-BP
have been shown to exert anti-tumour effects in vitro through
apoptosis induction and several other mechanisms [3, 94]. ZOL
inhibits tumour cell adhesion to the extracellular matrix,
invasion, and angiogenesis [3]. IBA prevented adhesion and
spreading of tumour cells to bone and tumour cell invasion.
These inhibitory effects were additive when IBA was given with
paclitaxel or docetaxel. In animal models of tumour-induced
osteolysis, IBA significantly reduced the development of
osteolytic lesions [94]. ZOL and IBA were also shown to exert
synergistic antitumour activity when combined with various
other anticancer agents [95–99], with some evidence for higher
in vitro efficacy with ZOL [99].
These preliminary data indicate that N-BP might have
clinical antitumour effects by themselves or in combination
with other anticancer treatments such as chemotherapy,
hormone therapy, radiotherapy [100, 101], or monoclonal
antibodies. However, special caution should be exerted when
administering cytotoxic drugs that can be nephrotoxic, such
as platinum salts, some antibiotics, and nonsteroidal
anti-inflammatory drugs (NSAIDs). The panel indicated that
nephrotoxic chemotherapy should not be administered on the
same day as an i.v. BP to reduce the risk of renal toxicity.
AE associated with BP therapy for
metastatic cancer
BP therapy for metastatic cancer is generally well tolerated, with
a low rate of (AE) in clinical practice [102]. Patients should be
instructed to recognize and report signs and symptoms
indicating key AE, and both the occurrence and severity of AE
should be monitored at each visit. Monitoring must include
questioning for AE and appropriate evaluation of CrCl in
patients receiving i.v. BP.
AE commonly associated with BP are generally manageable.
Side-effects related to BP pharmacology include osteomalacia
and (an AE associated with 1st generation but not observed
with 2nd or 3rd generation BP) hypocalcaemia. AE unrelated to
the anti-resorptive effect of BP include acute-phase reactions,
GI problems, local reactions at the injection site, and more
rarely nephrotoxicity and uveitis. Osteonecrosis of the jaw
(ONJ) has been described in recent years in association with the
use of BP.
‘Hypocalcaemia’ is typically observed in conditions of high
bone turnover, such as in mixed or sclerotic lesions. Clinically
relevant hypocalcaemia is very rarely observed and may be
prevented with calcium and vitamin D3 from the start of
therapy. A transient increase in ‘bone pain’ is seen mostly in
patients with painful bone lesions associated with aggressive
bone resorption treated with i.v. BP; it is usually mild and
transient and can be managed with preventive or therapeutic
analgesics. Transient ‘acute-phase reactions’ characterized by
fever and myalgia occurs in 15%–30% of patients [103],
generally after the first infusion of an N-BP, less frequently after
the following infusions. They peak within 24–48 h and subside
after 3 days [104]. They are no reason for treatment
discontinuation and can be managed with preventive or
therapeutic analgesics (e.g. paracetamol or ibuprofen (expert
consensus, despite of this being an NSAID).
‘Nephrotoxicity’ characterized by elevation of serum
creatinine level and potentially acute tubular necrosis with
reversible or irreversible kidney damage may occur in patients
receiving i.v. BP [105]. Grade 3 creatinine elevations have been
observed in three (3.3%) of prostate cancer patients treated
with 4 mg ZOL and in one (1.3%) receiving a placebo [54].
Renal effects are generally seen after rapid infusion leading to
high BP concentrations in the blood and kidney. Medline
reports on creatinine elevation were more frequent with ETI or
CLO (8% and 5%, respectively) than with PAM (2%),
alendronate (0%), or IBA (<1%) [106], the difference reaching
statistical significance for ETI only. No significant difference in
renal tolerability was seen in a pair wise comparison of PAM
(90 mg i.v. >2 h) and ZOL (4 mg i.v. >15 min) in a large clinical
trial in breast cancer [36]. ZOL can be safely administered with
proper serum CrCl evaluation, in cancer patients previously
treated with i.v. BP [107]. In a phase III trial of patients with
MBD from breast cancer, 6 mg IBA infused >1–2 h had a renal
safety profile comparable to that of placebo [108, 109].
Manufacturers’ recommendations for infusion times [63, 64,
72, 73] should be followed to minimize the potential for renal
AE since Cmax determines the nephrotoxicity of BP. To avoid
renal toxicity with i.v. BP, patients need to be adequately
hydrated before treatment, and monitoring of serum creatinine
is recommended [110].
GI problems with oral BP include mild gastric irritation,
erosions, and diarrhoea, and rarely ulcers, perforations, and
strictures. The more severe GI AE are uncommon with weekly
dosing regimens. Patients should be instructed to comply well
with the dosage prescriptions [fasting ‡1–2 h before and ‡1 h
after intake (except water), in the case of oral IBA upright
position for ‡1 h after intake] [63, 64]. Local reactions at the
injection site include phlebitis, pain, local swelling, and
ulceration. ‘Uveitis’ is rare and usually resolves within 1–2
weeks of treatment cessation.
ONJ is an uncommon but potentially serious complication
predominantly seen in patients receiving potent i.v. N-BP [111]
including PAM, ZOL [112, 113] and IBA [114], observed
mostly during treatment for multiple myeloma or breast cancer
[102, 111]. ONJ was also seen in a few patients treated with oral
alendronate and RIS for osteoporosis or Paget’s disease [112,
115, 116], and was recently reported in one multiple myeloma
patient treated with CLO [117]. The aetiology of ONJ is
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unclear but likely multifactorial [116]. Actinomyces has been
found frequently in these lesions [118], indicating that
osteomyelitis at sites of dental/jaw trauma may contribute to
the condition. There is a strong association with dental
pathology and interventions [102, 111, 112, 119, 120]. At least
60% of cases occur after dentoalveolar surgery to treat
infection, and the remainder often involves patients with
dentures [111]. The risk of experiencing ONJ seems to be time-
and dose dependent [111]. Other potential risk factors include
chemotherapy [114], glucocorticosteroids [102], and
thalidomide [102].
Best practices for identifying, staging and managing ONJ in
oncology patients on i.v. N-BP have been proposed [111, 116].
Preventive strategies aim at avoiding dental infection and
dentoalveolar surgery. Before starting i.v. N-BP treatment,
patients should have a dental examination and any treatment
required [116]. They must be advised to keep good oral
hygiene, have active oral infections treated, and sites at high
risk for infection eliminated. Patients with dental problems
other than ONJ should get the least invasive dental treatment.
Until healing of invasive dental surgery, temporary
discontinuation of BP therapy may be considered [116],
although there are no data available on which to make a firm
recommendation and the decision to stop or continue should
be made on a case by case basis.
prevention of CTIBL
Patients receiving adjuvant anticancer treatment are at
significant risk of CTIBL, including osteopenia and
osteoporosis. Cytotoxic chemotherapy (CT) and hormone
deprivation therapies can directly affect bone mineral density
(BMD) and micro-architectural structure [121–127].
Aromatase inhibitors (AIs) or gonadotropin-releasing hormone
agonists used in patients with breast or prostate cancer may
result in a two- to 10-fold higher yearly bone loss compared
with a healthy age-matched population [128–130]. Accelerated
bone loss increases fracture risk and has long-term implications
for QoL, costs, and even survival [131, 132]. Starting adjuvant
endocrine therapy of early breast cancer with tamoxifen and
switching to an AI after 2–3 years does not prevent a significant
increase in fractures in spite of prior bone protective effect of
tamoxifen [126].
In premenopausal women with CT-induced estrogen
depletion and antiestrogen therapy, CLO and RIS, respectively,
reduced bone loss significantly compared with placebo [133–
135]. PAM stabilized bone loss in androgen-deprived patients
with prostate cancer [130]. Alendronate is approved for the
treatment of osteoporosis in men and 70 mg once weekly
significantly increased bone mass at the spine and the total hip
in men with nonmetastatic prostate cancer on androgen
deprivation therapy [136]. To date, ZOL is the most intensively
investigated BP in this setting and long-term data in CTIBL in
large ongoing trials accruing several thousand patients in total
[22, 137–139] have shown ZOL to prevent or slow bone loss
during adjuvant endocrine therapy. In premenopausal patients
treated with anastrozole and goserelin, ZOL prevented bone
loss in lumbar spine and hip, regardless of endocrine therapy
(P < 0.0001) [19]. When added to adjuvant letrozole in
postmenopausal patients, ZOL (4 mg every 6 months) was
most effective when initiated before osteoporosis or fractures
occur [3.3%, 95% confidence interval (CI) 2.8% to 3.8%; P <
0.0001] [20, 21]. Patients treated with delayed ZOL (i.e. after
a fracture or a T-score less than 22) experienced a reduction in
spine and hip BMD [139]. Similarly, in nonmetastatic prostate
cancer, ZOL (4 mg every 3 months or once a year [140])
increased BMD in the spine in the first year of androgen
deprivation therapy, whereas BMD decreased in patients
receiving placebo (7.8%, 95% CI 5.6% to 10.0%; P < 0.001)
[141]. Prevention of bone loss has also been demonstrated with
long-term (2–3 years) CLO therapy in the adjuvant setting
[135, 142, 143]. These results are of particular importance in
patients who are osteopenic at baseline.
The combination of ZOL with hormone deprivation
therapy is well tolerated. No cases of ONJ were so far reported,
and renal function was not affected in this otherwise healthy
patient population [19, 21]. In a double-blind, placebo-
controlled trial in osteopenic breast cancer patients on
anastrozole, IBA 150 mg orally once a month resulted
in significant increase in BMD at the hip and lumbar spine
(P < 0.001) [144].
The panel recommends that patients at risk of developing
cancer treatment-induced osteopenia or osteoporosis should
receive vitamin D3 and calcium supplements. The use of BP
should be considered in patients presenting risk factors related
either to their BMD or other considerations described below.
These risk factors include aromatase inhibitors, T-score
£21.5, age >65, corticosteroid use of >6 months, family history
of hip fracture or history of personal fragility fracture after age
50 [145]. Patients should preferably receive a BMD test (dual
energy X-ray absorptiometry (DXA)). Where no BMD test is
available their risk is evaluated considering the risk factors as
following: a patient with 2 or more of them should be
considered for ZOL therapy supplemented with vitamin D3 and
calcium; similar considerations apply to patients with a T-score
less than 22.0 or a T-score less than 21.5 plus one other risk
factor [145].
future uses of BP
Three clinical trials investigating CLO as adjuvant therapy have
been reported, and two indicate that BP may prevent bone
metastasis [22, 146–148]. Two studies, one open-label study
from Germany [146] and a randomised double-blind placebo-
controlled trial from Canada, Norway, Finland, and UK [22]
reported improved overall survival while a third, open-label
study from Finland [147, 149] showed no effect on overall
survival and initially reported a reduced disease-free survival
and an increase in extra-skeletal metastases with CLO [147].
Marked imbalance in patient characteristics in the two groups
weakens, however, the findings of that particular study. In
the German study, a significant reduction of bone metastasis
after 3 years median follow-up was no longer significant after 8.6
years [150], yet survival in the CLO armwas 80% compared with
58% in the placebo arm (P = 0.049), indicating a lasting overall
survival gain from adjuvant CLO [22]. Recently, a meta-analysis
carried out in patients with early and advanced breast cancer
found no evidence of a statistically significant survival benefit in
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patients receiving CLO therapy [151]. Although these results
with CLO have not led to the registration with an indication for
use in the setting of adjuvant breast cancer treatment, they
indicate that BP may play a role in preventing bone metastasis
with optimized treatment schedules or choice of drug. This is
supported by the results of pilot studies [152, 153], one of which
reported adjuvant ZOL to increase 12-month bone metastasis-
free survival in aggressive solid tumors [152].
A large trial program (ABCSG-12, NSABP-B-34, AZURE,
S0307, SUCCESS; total accrual 18 000 patients) is further
exploring the use of BP as adjuvant therapy in patients with
breast cancer. The first safety analyses of the AZURE trial in
3360 patients indicate that the combination of adjuvant
chemotherapy and ZOL is well tolerated, with no significant
difference in the profile or severity of AE between groups [154].
NSABP-B-34 is a placebo-controlled phase III trial of adjuvant
CLO for the prevention of bone metastases in patients with
operable breast cancer. Accrual of 3323 patients was completed
in 2004 and results are expected for 2009. S0307 is
a randomized phase III head-to-head comparison of i.v. ZOL
acid with oral IBA or CLO for the prevention of bone
metastases in women with early breast cancer. Primary
end point is disease-free survival and target accrual is 6000
patients. ABCSG-12 is a prospective randomized trial
comparing preventive ZOL use without BP treatment in
premenopausal patients with endocrine-responsive breast
cancer who receive goserelin + tamoxifen/anastrozole. Accrual
of 1801 patients was finalized in 2006, and event-free survival is
the primary end point. The German trial SUCCESS (primary
end point disease-free survival) has recently completed the
enrolment of 3700 early high-risk BC patients, receiving ZOL
for 2 or 5 years following adjuvant chemotherapy.
Additional five randomized trials are ongoing to investigate
the potential of ZOL to prevent bone metastasis in prostate and
lung cancer. Mainly important are the ZEUS trial in prostate
with completed enrolment (1420 patients), comparing 4
year-ZOL versus observation, and the 2419 trial run in stage
IIIA–IIIB NSCLC patients, comparing 24-month-ZOL
versus observation.
Pending the results from one or more of the definitive studies
listed above, the panel does not recommend the use of adjuvant
BP to prevent metastases.
summary of panel recommendations
 In breast cancer, an N-BP is preferably offered to patients
with MBD. Generally, i.v. administration is preferable;
however, oral administration should be considered for
patients who cannot or do not have to attend regular hospital
care.
 For patients with hormone refractory prostate cancer, ZOL
therapy should be considered for preventing skeletal
morbidity and improving QoL, based on evidence.
 Patients with lung, renal cell or solid tumours other than
breast or prostate metastasizing to bone, ZOL therapy should
be considered based on assessment of their general medical
condition and expected survival time.
 BP therapy is a major factor contributing to control of pain
due to MBD.
 Patients at risk of developing chemotherapy or hormone-
deprivation therapy-induced or hormone deprivation
therapy-induced (e.g. by AI or ADT) osteopenia or
osteoporosis should be considered for preventative BP
therapy. Presently the strongest evidence is on favour of ZOL.
 Dosing regimens of BP therapy should follow the scientific
data and respective regulatory recommendations and
adjustments due to preexisting medical conditions.
 Since the risk of SREs is continuous, the expert panel
recommends continuing treatment until 2 years, even if a patient
experiences a bone event. Continuation of therapy beyond 2
years based on an individual risk assessment is recommended.
 Transient acute-phase reactions are no reason for treatment
discontinuation and can be managed with preventative or
therapeutic analgesics (e.g. paracetamol or ibuprofen).
 In patients with renal impairment receiving i.v. BP, lower
doses, longer infusion times, and selecting a BP with best
possible renal tolerability (e.g. IBA) is recommended.
 To avoid renal toxicity with i.v. BP, patients should be
adequately hydrated before treatment, and appropriate
monitoring of serum creatinine is recommended.
 Calcium and vitamin D3 should be considered from the start
of therapy with BP.
 In case of oral administration, patients need to be instructed
to comply well with the dosage prescriptions to prevent GI
problems and maintain the adherence to therapy.
 Before starting N-BP treatment, patients should have a dental
examination and appropriate treatment and should be
advised to maintain good oral hygiene.
 For each patient with ONJ, an individual benefit/risk
evaluation should be carried out to assess continuation or
temporary discontinuation of BP therapy.
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